A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)
Status:
Terminated
Trial end date:
2016-07-14
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of
single doses of odanacatib in mature adolescents and young adults who are currently receiving
glucocorticoid therapy. The primary hypotheses for the study are that a single dose of
odanacatib is well tolerated in mature adolescents and following single dose administration
of odanacatib 50 mg, there is no clinically important difference in AUC0-inf between mature
adolescents and young adults.